297 related articles for article (PubMed ID: 18691937)
1. The effects of ramelteon in a first-night model of transient insomnia.
Zammit G; Schwartz H; Roth T; Wang-Weigand S; Sainati S; Zhang J
Sleep Med; 2009 Jan; 10(1):55-9. PubMed ID: 18691937
[TBL] [Abstract][Full Text] [Related]
2. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P
Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
[TBL] [Abstract][Full Text] [Related]
3. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
Mini LJ; Wang-Weigand S; Zhang J
Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
[TBL] [Abstract][Full Text] [Related]
4. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.
Erman M; Seiden D; Zammit G; Sainati S; Zhang J
Sleep Med; 2006 Jan; 7(1):17-24. PubMed ID: 16309958
[TBL] [Abstract][Full Text] [Related]
5. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
Wang-Weigand S; Watissée M; Roth T
Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
[TBL] [Abstract][Full Text] [Related]
6. Ramelteon for the treatment of insomnia.
Borja NL; Daniel KL
Clin Ther; 2006 Oct; 28(10):1540-55. PubMed ID: 17157111
[TBL] [Abstract][Full Text] [Related]
7. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
Roth T; Stubbs C; Walsh JK
Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
[TBL] [Abstract][Full Text] [Related]
8. Ramelteon: a novel approach in the treatment of insomnia.
Reynoldson JN; Elliott E; Nelson LA
Ann Pharmacother; 2008 Sep; 42(9):1262-71. PubMed ID: 18648020
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
Richardson G; Wang-Weigand S
Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
[TBL] [Abstract][Full Text] [Related]
10. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel.
Zee PC; Wang-Weigand S; Wright KP; Peng X; Roth T
Sleep Med; 2010 Jun; 11(6):525-33. PubMed ID: 20483660
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study.
Uchimura N; Ogawa A; Hamamura M; Hashimoto T; Nagata H; Uchiyama M
Expert Rev Neurother; 2011 Feb; 11(2):215-24. PubMed ID: 21306209
[TBL] [Abstract][Full Text] [Related]
12. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
[TBL] [Abstract][Full Text] [Related]
13. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.
Roth T; Seiden D; Wang-Weigand S; Zhang J
Curr Med Res Opin; 2007 May; 23(5):1005-14. PubMed ID: 17519067
[TBL] [Abstract][Full Text] [Related]
14. Ramelteon: a review of its therapeutic potential in sleep disorders.
Pandi-Perumal SR; Srinivasan V; Spence DW; Moscovitch A; Hardeland R; Brown GM; Cardinali DP
Adv Ther; 2009 Jun; 26(6):613-26. PubMed ID: 19568703
[TBL] [Abstract][Full Text] [Related]
15. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.
Mini L; Wang-Weigand S; Zhang J
Clin Ther; 2008 Jul; 30(7):1316-23. PubMed ID: 18691991
[TBL] [Abstract][Full Text] [Related]
16. Ramelteon: new drug. Insomnia: no role for risky placebos.
Prescrire Int; 2008 Oct; 17(97):183-6. PubMed ID: 19534018
[TBL] [Abstract][Full Text] [Related]
17. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and clinical safety of ramelteon: an evidence-based review.
Sateia MJ; Kirby-Long P; Taylor JL
Sleep Med Rev; 2008 Aug; 12(4):319-32. PubMed ID: 18603221
[TBL] [Abstract][Full Text] [Related]
19. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.
Karim A; Tolbert D; Cao C
J Clin Pharmacol; 2006 Feb; 46(2):140-8. PubMed ID: 16432265
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
